On Thursday February 7, 2019, KEI submitted comments and intent to testify at the hearing for the 2019 US Trade Representative’s Special 301 review process. This year’s hearing will take place on Wednesday February 27, 2019 at the Office of… Continue Reading
(UPDATE: The NIH provided a response to our comments on February 4, 2019) On January 7, 2019, KEI and MSF (Doctors Without Borders/Médecins Sans Frontières USA) submitted comments to the Federal Register notice (83 FR 65696) on the “Prospective Grant… Continue Reading
(UPDATE: The NIH provided a response to our comments on January 11, 2019) On Monday January 7, 2019, KEI submitted joint comments on behalf of Health GAP, Social Security Works, the Union for Affordable Cancer Treatment, and Professor Brook Baker… Continue Reading
DATE: December 10, 2018 Intent to Testify and Testimony Summary/Comments on Negotiating Objectives for a U.S.-European Union Trade Agreement (USEUTA) Luis Gil Abinader. Knowledge Ecology International 1621 Connecticut Avenue, Northwest, Suite 500, Washington, DC 20009. Phone number +1.202.332.2670. Federal Register… Continue Reading
The following are comments by KEI, UACT, Social Security Works, HealthGap, Public Citizen, Dr. Ophira Ginsbug and James Love on an NIH proposed exclusive license for patents on a CAR T technology for “Treatment of FMS-Like Tyrosine Kinase 3 (FLT3)… Continue Reading
This October 11, 2017 email, from Catherine Robinson of Pfizer to Daniel Watson and John Meile of USTR, asks USTR to block a competitor from a tender to sell a drug. USTR provides one email and redacts details including the… Continue Reading
The panel in a WTO dispute regarding Australia and plain packaging of tobacco products reached the conclusion that 2001 Doha Declaration on the TRIPS Agreement and Public Health has the status of an agreement that has modified the interpretation of… Continue Reading
Below are the comments filed by Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) regarding a prospective grant of an exclusive license of NIH-owned patents to the California-based company Midissia Therapeutics. The prospective exclusive license is… Continue Reading
On July 18, 2018, the U.S. House Energy and Commerce committee gave its approval to HR 6378, the Pandemic and All-Hazards Preparedness Act, known as PAHPA. During the mark up, Reps. John Shimkus (R-IL) and Tony Cárdenas (D-CA) proposed attaching… Continue Reading
The following are comments by the KEI on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to notice in the Federal Register, 83 FR 22692. Overall, the Blueprint is very weak, and won’t do much… Continue Reading